

Current Patents Gazette

ISSUE 0639 29th September 2006

DOLPHIN



The records appearing in this Gazette will be added to DOLPHIN, the database Of all pharmaceutical inventions in the next week. Based on the INPADOC database produced by the European Patent Office, it covers all national and international patents with relevance to pharmaceutical research and development published from 1968 onwards and selected patents from earlier years. DOLPHIN contains information on bibliographic data, contents, associated products, legal status, licensees and context of patents, which is presented in a format to convey all aspects of a patent at a glance.

News & Highlights from Week 0639

There are no SPC events recorded in the UK Patents and Designs Journal (PDJ 6123) this week. However, we have received the Japanese patent gazette published September 25, which contains details of one granted patent extension.

The extension is granted to the **Beecham Group PLC** (now **GlaxoSmithKline**) and provides a five year extension on granted Japanese patent JP06047587 for **paroxetine**. This particular extension covers the use of paroxetine in treating obsessive-compulsive disorder (OCD), which was approved in Japan earlier this year. A five year extension covering paroxetine itself had already been granted previously and as with the current extension, will extend the life of JP06047587, which would have expired in one month, until October 24, 2011. Paroxetine, marketed as **Seroxat** or **Paxil** has been the source of much litigation in the USA, caused by several Paragraph IV filings and which has resulted in several generic versions appearing already. Despite this growing generic competition, paroxetine achieved sales of \$1.075 billion in 2005. Although this was a 42% year-on-year decline, this was compounded by supply problems for **Paxil CR** (the controlled release form of paroxetine) caused by the FDA initiated seizures in March 2005 at three sites in response to concerns about manufacturing quality. Current year sales are expected to recover somewhat, with analysts for our Strategic Drugs database (SDdb) predicting 2006 sales of around \$1.7 billion, supported by approvals for additional indications worldwide, such as the OCD approval and patent extensions in Japan.

Angiomed GmbH & Co Medizintechnik KG has filed an UK initial ("A0") application for a self-expanding stent. Previous stent-related applications include WO2006010638, WO2006010636 and WO2004098692. In May 2006, Angiomed signed a cooperation

and research agreement with Finnish company **Inion**, to develop biodegradable peripheral vascular stents. The collaboration will combine Inion's expertise in biodegradable materials technology with **Angiomed's** expertise in the design and development of vascular stents, and this marks the first development agreement with Inion's Optima technology outside the orthopedic area.


BiotechGen Ltd has filed three applications this week, all relating broadly to the use of molecules for the treatment of disease (unspecified) and screening methods. These are likely to continue on from applications filed in August of this year by Keith Moyses, MD of the Oxford-based company focussing on angiogenesis inhibitors and cancer therapies.

Cambridge Consultants Ltd has added to their extensive portfolio of inhalers with an application entitled drug capsules for dry powder inhalers. This is likely to be related to WO2006061637, filed in June 2006 entitled "dry powder inhalers". The company's new dry powder inhaler technology, **NEXT**, was presented for the first time at the Respiratory Drug Delivery conference in Florida on April 23 to 27, 2006. The **NEXT DPI**, designed in conjunction with **Chiesi Farmaceutici**, consistently achieves a high fine particle fraction and has successfully completed pharmacokinetic clinical studies.

UCB S.A. is seeking protection for a selection of "therapeutic agents" this week. UCB has a strong product line in CNS (**Keppra® (levetiracetam)**, **Nootropil® (piracetam)** and **Metadate-CD™/Equasym™ (methylphenidate HCl)**) as well as allergy & respiratory (eg **Xyzal® (levocetirizine)**, **Zyrtec® (cetirizine)** and **Tussionex™**). Two emerging research areas of interest to the company are digestive tract (**Somatostatin-ucb** and **Stogar®**) and bladder disorders (**Kentera®** and **BUP-4™**); and already have a couple of candidates per

indication on the market. Oncology, another area of interest, does not appear to have resulted in any launched products as yet, according to the company's website. Just a couple of days ago (25th Sept 2006) **UCB** announced its proposed acquisition of **Schwarz Pharma**; should this see completion this will strengthen UCB's pipeline predominantly in the field of cardiovascular research, in which Schwarz specializes, but will also expand upon UCB's CNS pipeline.

KU Leuven Research & Development is seeking protection for a "Novel therapy for joint disorders". This appears to be the first application directly for joint disorders, the closest previous filings are with respect to bone disorders using vitamin D analogs.



Thiazolidine-2,4-dione inhibitors of CDC25B phosphatase for the treatment of uterine cancer. A new area of research for Korea Research Institute of Chemical Technology

Current Patents Gazette

UK initial ("A0") applications filed August 16th - 21st 2006

Angiomed GmbH & Co Medizintechnik KG is seeking protection for a self-expanding stent. Previous stent-related applications include **WO2006010638**, **WO2006010636** and **WO2004098692**. In May 2006, **Angiomed** signed a cooperation and research agreement with Finnish company **Inion**, to develop biodegradable peripheral vascular stents. The collaboration will combine **Inion's** expertise in biodegradable materials technology with **Angiomed's** expertise in the design and development of vascular stents, and this marks the first development agreement with **Inion's** Optima technology outside the orthopedic area.

Argenta Discovery Ltd has filed an application titled "compounds and their use". Recent applications from Argenta relating to new compounds include **WO2006082412** (heterocyclic multimers, HNE inhibitors), **WO2006050965** (pyrimidine compounds, histamine modulators), **WO2005035521** (substituted quinolines, MCH modulators), **WO2005035526** (ortho-fused bicyclic derivatives, MCH modulators) and **WO2005012263** (pyrimidine, oxazole, imidazole and triazole derivatives, 5-HT_{2B} antagonists). In July 2006, **Argenta** entered into collaboration with **AstraZeneca LP**, involving optimization of a series of hits by the design and synthesis of novel analogs. **Argenta's Steve Price** (a named inventor on **WO2006050965**) presented a novel weak HDAC inhibitor, **ADS-100380**, at the XIXth International Symposium on Medicinal Chemistry, held in Istanbul, Turkey, from 29 August to 2 September 2006.

BiotechGen Ltd has filed three applications this week, all relating broadly to the use of molecules for the treatment of disease (unspecified) and screening methods. These are likely to continue on from applications filed in August of this year by **Keith Moyse**, MD of the Oxford-based company focussing on angiogenesis inhibitors and cancer therapies.

Cambridge Consultants Ltd has added to their extensive portfolio of inhalers with an application entitled drug capsules for dry powder inhalers. This is likely to be related to **WO2006061637**, filed in June 2006 entitled "dry powder inhalers". The company's new dry powder inhaler technology, **NEXT**, was presented for the first time at the Respiratory Drug Delivery conference in Florida on April 23 to 27, 2006. The **NEXT** DPI, designed in conjunction with **Chiesi Farmaceutici**, consistently achieves a high fine particle fraction and has successfully completed pharmacokinetic clinical studies.

Cambridge University Technical Services Ltd is seeking protection for an application relating to biomarkers and their uses. This continues on from two applications made in July 2006 having the same titles, **WO2006085122** and **WO2006085121**, both claiming VGF peptide biomarkers for schizophrenic, bipolar or psychotic disorders.

Henderson Morley Plc has lodged a couple of UK initial applications entitled "Treatment of Pain" and "DNA Viral infections". The former appears to be the first application relating to pain from the company; the latter application is likely to relate to the company's DNA technology for viral infections. In particular, **WO0149242** and **WO2005102351** claim compositions comprising a synergistic combination of a diuretic and cardiac glycoside, the latter specifically for treating DNA viral infections of the eye. See also **WO0224207** comprising diuretic agents or sulfonylurea compounds for treating DNA viral infections.

KU Leuven Research & Development is seeking protection for a "Novel therapy for joint disorders". This appears to be the first application directly for joint disorders, the closest previous filings are with respect to bone disorders using vitamin D analogs.

Inventor **John Morley** has lodged a UK initial application for the "reatment for neuropathic pain". The inventor, who may be affiliated with the **University of Liverpool**, does not appear to have filed previously in the therapeutic area of pain.

The Royal Veterinary College has lodged a UK initial application entitled "methods and compositions". **DOLPHIN** reports nine previous applications from this research institution, which indicate a keen interest in viral therapeutics. While some pertain **Canine Respiratory CoronaVirus** (CRCV) and **Canine Infectious Respiratory Disease** (CIRD), at least five have been identified to have some pharmaceutical relevance; the most recent of which is **WO2005056051**, on HBV vaccines.

UCB S.A. is seeking protection for a selection of "therapeutic agents" this week. UCB has a strong product line in **CNS** (Keppra® (**levetiracetam**), Nootropil® (**piracetam**) and Metadate-CD™ / Equasym™ (**methylphenidate HCl**)) as well as **allergy& respiratory** (eg Xyzal® (**levocetirizine**), Zyrtec® (**cetirizine**) and **Tussionex**™). Two emerging research areas of interest to the company is digestive tract (**Somatostatin-ucb** and **Stogar**®) and bladder disorders (**Kentera**® and **BUP-4**™); and already have a couple of candidates per indication on the market. Oncology, another area of interest, does not appear to have resulted in any launched products as yet, according to the company's website. Just a couple of days ago (25th Sept 2006) UCB announced its proposed acquisition of **Schwarz Pharma**; should this see completion this will strengthen UCB's pipeline predominantly in the field of cardiovascular research, in which Schwarz specializes, but will also expand upon UCB's CNS pipeline.

Istituto di Ricerche di Biologia Molecolare (IRBM) P Angeletti SpA is seeking protection for an application entitled therapeutic compounds. The Merck Sharpe and Dohme subsidiary's main research interests lie in antiviral and cancer therapy, particularly HCV and HIV infections.

Pliva Istrazivanje I Razvoj DOO has filed an application entitled process. Pliva's previous applications claiming processes appear to be based mainly in the antimicrobial area, particularly relating to antibacterial agents.

Due for publication in February 2008